Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460481 | 0.82 | CYP2A6 (0.45) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL2320126 | 0.78 | CYP2A6 (0.38) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL4446667 | 0.76 | CYP2A6 (0.36) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL7609958 | 0.76 | CYP2A6 (0.36) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6855349 | 0.76 | CYP2A6 (0.36) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28762438 | 0.76 | LMNA (0.37) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL14708718 | 0.73 | GABRA1 (0.43) | CYP2A6CYP1A2ALDH1A1TSHRCA1 | |
| SCHEMBL13895541 | 0.73 | GABRA1 (0.43) | ALDH1A1SCN4ATDP1LMNAHSD17B10 | |
| SCHEMBL23328219 | 0.71 | ALDH1A1 (0.38) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL22564870 | 0.71 | ACHE (0.50) | CYP2A6CYP1A2ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044048-A1 | (R)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2004-03-04 | — | — | US | claimed |
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-12-04 | — | — | US | claimed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
| US-6476057-B1 | ANTICHOLESTEROL AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | claimed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | claimed |
| US-6803388-B2 | TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASES; STEREOSELECTIVE; CHEMICAL INTERMEDIATES | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6723752-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710089-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | PHARMACIA CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20040044048-A1 | (R)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2004-03-04 | — | — | US | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| US-6696472-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6479552-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-11-12 | — | — | US | disclosed |
| US-6476057-B1 | ANTICHOLESTEROL AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | disclosed |
| US-6462092-B1 | SUCH AS 3-((3-FLUOROPHENYL)-((3-(TRIFLUOROMETHYL)PHENYL)-METHYL)AMINO)-1,1,1 -TRIFLUORO-2-PROPANOL; CARDIOVASCULAR DISEASE, I.E. ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-10-08 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | disclosed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CYP2A6 3016/4885CYP1A2 2762/4885ALDH1A1 2624/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CYP2A6 3016/4885CYP1A2 2762/4885ALDH1A1 2624/4885 |
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, MTTP | CYP2A6 1643/4885CYP1A2 2903/4885ALDH1A1 2516/4885 |
| US-20040044048-A1 | (R)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CYP2A6 2867/4885CYP1A2 1960/4885ALDH1A1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.